Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients.
about
Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance.The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes.A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes MellitusLocus of control and obesity.Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetesThe efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjectsPharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.Alogliptin benzoate for the treatment of type 2 diabetes.Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients.Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes MellitusEfficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus.
P2860
Q33603416-1DB58296-5D11-4DEF-A29B-2D09272D97A9Q33619167-948E3D67-5047-496C-BD47-11D1A261F284Q33763289-D2612441-6CC5-4200-9235-BE90C6E76BE9Q33775600-068184EE-5A81-4F96-B9FA-403DD9E3CFDDQ34299762-E841FBCB-D83F-4570-9697-C9C9D12D58BFQ35087917-34C671EC-09C0-444D-84D2-7167604142C2Q35166849-E8BA8537-8AC0-4FED-9552-A8174BAAFD45Q36508312-D23723B5-2303-4DDE-924D-B8B3837F9C29Q36917168-2B93A194-C3B1-4939-8AD5-11F48D11129DQ37331331-40DC0EA3-2EEE-473A-962C-1A354514C6F6Q38122004-9AF7F675-2D57-4FBD-B7C8-54173CF10F9FQ38197275-65F9544A-56FC-4C92-88EC-D10FFC50B718Q38614486-5A64B2E6-68C5-4939-A0B3-BA6F1D328A43Q42279452-3BF6DB9A-8A0F-48F3-ADD0-FC2028DD01EAQ48286589-CFC4AEC1-693F-4948-BF04-78453F813456
P2860
Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Obesity may attenuate the HbA1 ...... nese type 2 diabetic patients.
@ast
Obesity may attenuate the HbA1 ...... nese type 2 diabetic patients.
@en
type
label
Obesity may attenuate the HbA1 ...... nese type 2 diabetic patients.
@ast
Obesity may attenuate the HbA1 ...... nese type 2 diabetic patients.
@en
prefLabel
Obesity may attenuate the HbA1 ...... nese type 2 diabetic patients.
@ast
Obesity may attenuate the HbA1 ...... nese type 2 diabetic patients.
@en
P2093
P2860
P1476
Obesity may attenuate the HbA1 ...... nese type 2 diabetic patients.
@en
P2093
Azusa Hisada
Daisyu Toya
Hideo Kanehara
Keiko Aoki
Nobuyoshi Tanaka
Yukihiro Bando
P2860
P304
P356
10.1111/J.2040-1124.2011.00156.X
P577
2012-03-01T00:00:00Z